Fiche publication
Date publication
décembre 2014
Auteurs
Membres identifiés du Cancéropôle Est :
Pr MAYNADIE Marc
,
Dr WORONOFF Anne-Sophie
Tous les auteurs :
Penot A, Preux P, Le Guyader S, Collignon A, Herry A, Dufour V, Monnereau A, Woronoff A, Troussard X, Pons E, Bordessoule D, Maynadie M
Lien Pubmed
Résumé
ABSTRACT Treatment of chronic myeloid leukemia (CML) has seen several major advances over the past 30 years, notably with the introduction of interferon followed by Bcr-Abl tyrosine kinase inhibitors. We analyzed trends in the incidence of CML and patient survival in France. All cases recorded in five population-based registries between 1980 and 2009 were included. European (ESR) and world (WSR) standardized incidence rates as well as relative survival (RS) rates were estimated. We analyzed data for 781 patients (9863/3: 13.6%; 9875/3: 82.2%; 9876/3: 4.2%; mean age: 57.4 years). ESR was 1.02 [95%CI= 0.93-1.11] and WSR 0.81 [95%CI= 0.72-0.90]. The 5- RS rates among patients with Ph+_CML were 43.7% [30.9-61.9] when diagnosed in 1980-1986, 63.8% [56.9-71.5] in 1987-1999 and 88.7% [84.5-93.0] in 2000-2009. The eight-year RS rate of patients with Ph+_CML diagnosed in 2000-2009 was 83.3% [77.5-89.4]. Therapeutic innovations have thus led to a significant increase in long-term survival in the general CML patient population.
Référence
Leuk Lymphoma. 2014 Dec 23:1-38.
